Rexahn Astounds With New Cancer Data

Feb. 23, 2016 8:52 AM ET
by: Sharon di Stefano

Summary

  • Pillbased targeted cancer data for pancreas, kidney and breast show efficacy and safety.
  • Widely-attended scientific conferences gain exposure to Supinoxin’s clinical merit.
  • Supinoxin targets cancer’s genes, proteins, blood supply and surrounding tumor tissue to block growth and cause shrinkage without damage to healthy cells.
  • Rexahn brings Archexin for kidney cancer to the next important level.
  • Whether larger trials can replicate former success is a risk.

- Seeking Alpha -

Click here for more information